GI Oncology Now Conference Coverage
GI Oncology Now reviews education from ASCO GI 2024, featuring the latest advances in the field of GI cancer research.
Coverage of the 2024 ASCO GI Symposium, focusing on liver cancer
GI Oncology Now reviews education from ISGIO 2023, featuring the latest advances in the field of GI cancer research.
GI Oncology Now reviews practice-enhancing education from CIO 2023, featuring multidisciplinary specialties in oncology.
Advertisement
The Latest From GI Oncology Now
A recent study utilized patient data from 13 medical centers in a biomarker analysis of 1L ICIs with & without ...
A recent observational study determined if there is a correlation between the improvement of ADR and lower rates of CRC.
The designation is based on positive results from an ongoing collaborative trial between GSK and MSK Cancer Center.
Dr. Joseph Cullen discusses the combination of vitamin C with gemcitabine and nab-paclitaxel for pancreatic cancer.
Dr. Cytryn provides insights on the FDA approval of zolbetuximab and how it will impact clinical practice.
Rising HCC mortality rates in the US highlight stark disparities across age, sex, race, and liver disease etiologies.
Both of the double-blind, multicenter trials evaluated the major efficacy outcomes of PFS and OS.
The GAP system was found to predict actionable genetic alterations including FGFR2 and IDH.
Advertisement
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.